JPRN-UMIN000001998已完成2 期
A phase II trial of FOLFIRI combined with hyperthermia as second-line therapy of unresectable colon cancer with liver metastases - Combination therapy of FOLFIRI and hyperthermia in unresectable colon cancer with liver metastases
Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine0 个研究点目标入组 25 人开始时间: 2009年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who has received blood transfusion, blood products, and medicine made of blood formation factor within seven days of registration. 2.Medical history of severe hypersensitivity. 3.Massive ascites, pleural or pericardial effusin that required drainage. 4.With active infection. 5.With brain metastasis 6.With active double cancer. 7.Presence of uncontrolled hypertension. 8.Presence of uncontrolled diabetes. 9.Presence of unstable angina, myocardial infarction within three months. 10.Active gastrtrointestinal bleeding. 11.With intestinal paralysis, intestinal obstruction. 12.With diarrhea. 13.Patients receiving Atazanabil. 14.Pregnant or nursing women, men or women who like be pregnant. 15.Inappropriate patients for this study judged by the physicians.
研究者
相似试验
进行中（未招募）
1 期
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaEUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112
进行中（未招募）
1 期
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
已完成
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G)first-line treatment in patients with metastatic colorectal cancerJPRN-UMIN000026527West Japan Oncology Group120
进行中（未招募）
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)JPRN-jRCTs041180166Kito Yosuke120
已完成
2 期
Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with exploratory analysis to predict treatment efficacy and prognosisColorectal cancerJPRN-UMIN000005216West Japan Oncology Group200